Keywords
How to Cite
Abstract
In a review article the relationship between benign prostatic hyperplasia (BPH) and prostate cancer (PC) has been conducted. Epidemiological data on increasing the risk of PC in patients with BPH are presented. There are discussed common for BPH and PC constitutional, food, and life style etiologic factors and also common for the both diseases pathogenetic factors such as androgens, inflammation, metabolic syndrome. Pharmaceutical drugs and natural agents that have unidirectional therapeutic and preventive effect on BPH and PC are presented. Results of experimental studies of the authors to prove the link between BPH and PC are presented. It is concluded that BPH is a risk factor for PC and, ideally, drugs for the treatment of BPH should have a chemopreventive effect on PC.References
Аполихин О.И., Сивков А.В., Бешлиев Д.А. и др. Анализ урологической заболеваемости в Российской Федерации в 2002-2009 годах по данным официальной статистики // Экспер. и клин. урол. - 2011. - № 1. - С. 4-10.
Аполихин О.И., Сивков А.В., Шишкин С.В. Медико-экономические аспекты комплексной этапной стандартизированной программы диагностики и лечения доброкачественной гиперплазии предстательной железы// Эксперим. и клин. урол. - 2014. - № 3. - С. 4-11.
Беспалов В.Г. Возможности применения нестероидных противовоспалительных средств для профилактики рака // Медлайн экспресс. - 2002. - № 11. -С. 24-27.
Беспалов В.Г., Муразов Я.Г., Кужанов А.А. Донозологическая химиопрофилактика рака предстательной железы с помощью биоактивного комплекса из хвои сосны и ели // Донозология и здоровый образ жизни. - 2014. - № 1. - С. 55-61.
Беспалов В.Г., Муразов Я.Г., Кужанов А.А., Семёнов А.Л. Сравнительное изучение простатотропных эффектов хвойного провитаминного концентрата и экстракта Serenoa repens на модели доброкачественной гиперплазии предстательной железы у крыс // Экспер. и клин. урол. - 2013. - № 2. - С. 30-34.
Беспалов В.Г., Муразов Я.Г., Панченко А.В. Химиопрофилактика рака предстательной железы: обзор клинических и доклинических данных // Экспер. и клин. урол. - 2011. - № 4. - С. 80-85.
Беспалов В.Г., Кужанов А.А., Майдин М.А. и др. Лекарственная терапия доброкачественной гиперплазии и химиопрофилактика рака предстательной железы // Вопр. онкол. - 2015. - Т. 61. - № 5. - C. 804-811.
Беспалов В.Г., Кужанов А.А., Семенов А.Н. и др. Химиопрофилактика рака и лечение доброкачественной гиперплазии предстательной железы с помощью комплекса природных веществ / Тезисы VIII Съезда онкологов и радиологов СНГ и Евразии. - Казань, 16-18 сентября 2014 г. // Евразийский онкологический журнал. - 2014. - № 3. - С. 89.
Беспалов В.Г., Некрасова В.Б., Шевченко И.А., Вершинин А.С. Провитам - биоактивный комплекс из хвои сосны и ели. - СПб.: Нордмедиздат, 2012. - 52 с.
Беспалов В.Г., Панченко А.В., Муразов Я.Г., Чепик О.Ф. Влияние селенита натрия на канцерогенез предстательной железы и других органов, индуцированных метилнитрозомочевиной и тестостероном у крыс // Вопр. онкол. - 2011. - Т. 57. - № 4. - С. 486-492.
Болезни предстательной железы / Под ред. Ю.Г. Аляева. - М.: ГЭОТАР-Медиа, 2009. - С. 126-152.
Воробьев А.В., Крживицкий П.И. Перспективы профилактики, диагностика и стадирование рака предстательной железы // Практ. онкол. - 2008. - Т. 9. - № 2. - С. 71-82.
Злокачественные новообразования в России в 2014 году (заболеваемость и смертность) / Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. - М.: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИРЦ» Минздрава России, 2016. - 250 с.
Имянитов Е.Н. Эпидемиология и биология рака простаты // Практ. онкол. - 2008. - Т. 9. - № 2. - С. 57-64.
Клиническая онкоурология / Под ред. Б.П. Матвеева. - М.: Российское общество онкоурологов, 2011. - С. 495-588.
Муразов Я.Г., Беспалов В.Г., Панченко А.В., Чепик О.Ф. Разработка экспериментальной модели фоновых, предопухолевых и опухолевых изменений предстательной железы // Ученые записки СПбГМУ им. акад. И.П. Павлова. - 2011. - Т.18. - № 3. - С. 51-54.
Практическая урология: Руководство для врачей / Под ред. П.В. Глыбочко, Ю.Г. Аляева. - М.: Медфорум, 2012. - 352 с.
Alcaraz A., Hammerer P., Tubaro A. Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review // Eur. Urol. - 2009. - Vol. 55. - P. 864-873.
Alkhenizan A., Hafez K. The role of vitamin E in the prevention of cancer: a meta-analysis of randomized controlled trials // Ann. Saudi Med. - 2007. - Vol. 27. - P. 409-414.
Andriole G.L., Bostwick D.G., Brawley O.W. et al. Effect of dutasteride on the risk of prostate cancer // N. Engl. J. Med. - 2010. - Vol. 362. - P. 1192-1202.
Arrighi H.M., Metter E.J., Guess H.A., Fozzard J.L. Natural history of benign prostatic hyperplasia and risk of prostatectomy. The Baltimore Longitudinal Study of Aging // Urology. - 1991. - Vol. 38 (1 Suppl.) - P. 4-8.
Arruzazabala M.L., Mas R., Molina V. et al. Effect of D-004, a lipid extract from the Cuban royal palm fruit, on atypical prostate hyperplasia induced by phenylephrine in rats // Drugs R.D. - 2006. - Vol. 7. - P. 233-241.
Azimi H., Khakshur A.A., Aghdasi I. et al. A review of animal and human studies for management of benign prostatic hyperplasia with natural products: perspective of new pharmacological agents // Inflamm. Allergy Drug Targets. - 2012. - Vol. 11. - P. 207-221.
Beuten J., Gelfond J.A., Franke J.L. et al. Single and multivariate associations of MSR1, ELAC2, and RNASEL with prostate cancer in an ethnic diverse cohort of men // Cancer Epidemiol. Biomarkers Prev. - 2010. - Vol. 19. -P. 588-599.
Bostwick D.G., Cooner W.H., Denis L. et al. The association of benign prostatic hyperplasia and cancer of the prostate // Cancer. - 1992. - Vol. 70 (1 Suppl.) -P. 291-301.
Brinkman M., Reulen R.C., Kellen E. et al. Are men with low selenium levels at increased risk of prostate cancer? // Eur. J. Cancer. - 2006. - Vol. 42. - P. 2463-2471.
Chokkalingam A.P., Nyrén O., Johansson J.E. et al. Prostate carcinoma risk subsequent to diagnosis of benign prostatic hyperplasia: a population-based cohort study in Sweden // Cancer. - 2003. - Vol. 98. - P. 1727-1734.
Choubey V.K., Sankhwar S.N., Tewari R. et al. Null genotypes at the GSTM1 and GSTT1 genes and the risk of benign prostatic hyperplasia: a case-control study and a meta-analysis // Prostate. - 2013. - Vol. 73. - P. 146-152.
De Nunzio C., Kramer G., Marberger M. et al. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation // Eur. Urol. - 2011. - Vol. 60. - P. 106-117.
Eichholzer M., Steinbrecher A., Kaaks R. et al. Effects of selenium status, dietary glucosinolate intake and serum glutathione S-transferase a activity on the risk of benign prostatic hyperplasia // BJU Int. - 2012. - Vol. 110. - P 879-885.
Endogenous Hormones and Prostate Cancer Collaborative Group, Roddam A.W., Allen N.E. et al. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies // J. Natl Cancer Inst. - 2008. - Vol. 100. - P 170-183.
Etminan M., FitzGerald J.M., Gleave M., Chambers K. Intake of selenium in the prevention of prostate cancer: a systematic review and meta-analysis // Cancer Causes Control. - 2005. - Vol. 16. - P. 1125-1131.
Fleshner N.E., Lawrentschuk N. Risk of developing prostate cancer in the future: overview of prognostic biomarkers // Urology. - 2009. - Vol. 73(5 Suppl.). -P. 21-27.
Fowke J.H., Phillips S., Koyama T. et al. Association between physical activity, lower urinary tract symptoms (LUTS) and prostate volume // BJU Int. - 2013. -Vol. 111. - P. 122-128.
Giovannucci E.L., Liu Y., Leitzmann M.F. et al. A prospective study of physical activity and incident and fatal prostate cancer // Arch. Intern. Med. - 2005. - Vol. 165. - P. 1005-1010.
Goetzl M.A., Vanveldhuizen P.J., Thrasher J.B. Effects of soy phytoestrogens on the prostate // Prostate Cancer Prostatic Dis. - 2007. - Vol. 10. - P. 216-223.
Hammarsten J., Högstedt B. Calculated fast-growing benign prostatic hyperplasia - a risk factor for developing clinical prostate cancer // Scand. J. Urol. Nephrol. - 2002. - Vol. 36. - P. 330-338.
Hammarsten J., Högstedt B. Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer // Eur. J. Cancer. - 2005. - Vol. 41. - P. 2887-2895.
Helfand B.T., Hu Q., Loeb S. et al. Genetic sequence variants are associated with severity of lower urinary tract symptoms and prostate cancer susceptibility // J. Urol. -2013. - Vol. 189. - P. 845-848.
Huncharek M., Haddock K.S., Reid R., Kupelnick B. Smoking as a risk factor for prostate cancer: a metaanalysis of 24 prospective cohort studies // Am. J. Public Health. - 2010. - Vol. 100. - P. 693-701.
Kristal A.R., Arnold K.B., Schenk J.M. et al. Race/ ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial // J. Urol. - 2007. -Vol. 177. - P. 1395-1400.
Kristal A.R., Arnold K.B., Schenk J.M. et al. Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial // Am. J. Epidemiol. - 2008. -Vol. 167. - P. 925-934.
Lamartiniere C.A., Cotroneo M.S., Fritz W.A. et al. Genistein chemoprevention: timing and mechanisms of action in murine mammary and prostate // J. Nutr. - 2002. - Vol. 132. - P. 552S-558S.
Ledesma M.C., Jung-Hynes B., Schmit T.L. et al. Selenium and vitamin E for prostate cancer: Post-SELECT (Selenium and Vitamin E Cancer Prevention Trial) status // Mol. Med. - 2011. - Vol. 17. - P. 134-143.
MacLennan G.T., Eisenberg R., Fleshman R.L. et al. The influence of chronic inflammation in prostatic carci nogenesis: a 5-year follow up study // J. Urol. - 2006. - Vol. 176. - P. 1012-1016.
McCormick D.L., Johnson W.D., Bosland M.C. et al. Chemoprevention of rat prostate carcinogenesis by soy isoflavones and by Bowman-Birk inhibitor // Nutr. Cancer. - 2007. - Vol. 57. - P. 184-193.
McVary K.T. BPH: epidemiology and comorbidities // Am. J. Manag. Care. - 2006. - 12 (5 Suppl.). - P. 122-128.
Messina M., Kucuk O., Lampe J.W. An overview of the health effects of isoflavones with an emphasis on prostate cancer risk and prostate-specific antigen levels // J. AOAC Int. - 2006. - Vol. 89. - P. 1121-1134.
Meyer M.S., Penney K.L., Stark J.R. et al. Genetic variation in RNASEL associated with prostate cancer risk and progression // Carcinogenesis. - 2010. - Vol. 31. -P. 1597-1603.
Mohanty N.K., Saxena S., Singh U.P. et al. Lycopene as a chemopreventive agent in the treatment of high-grade prostate intraepithelial neoplasia // Urol. Oncol. -2005. - Vol. 23. - P. 383-385.
Nandeesha H., Koner B.C., Dorairajan L.N., Sen S.K. Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia // Clin. Chim. Acta. - 2006. - Vol. 370. - P. 89-93.
Nemesure B., Wu S.Y., Hennis A. et al. Central adiposity and prostate cancer in a black population // Cancer Epidemiol. Biomarkers Prev. - 2012. - Vol. 21. - P. 851-858.
Nickel J.C., Roehrborn C.G., O Leary M.P. et al. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial // Eur. Urol. - 2008. - Vol. 54. -P. 1379-1384.
Orsted D.D., Bojesen S.E. The link between benign prostatic hyperplasia and prostate cancer // Nat. Rev. Urol. - 2013. - Vol. 10. - P. 49-54.
Orsted D.D., Bojesen S.E., Nielsen S.F., Nordestgaard B.G. Association of clinical benign prostate hyperplasia with prostate cancer incidence and mortality revisited: a nationwide cohort study of 3,009,258 men // Eur. Urol. -2011. - Vol. 60. - P. 691-698.
Parsons J.K. Benign prostatic hyperplasia and male lower urinary tract symptoms: epidemiology and risk factors // Curr. Bladder Dysfunct. Rep. - 2010. - Vol. 5. -P. 212-218.
Parsons J.K., Im R. Alcohol consumption is associated with a decreased risk of benign prostatic hyperplasia // J. Urol. - 2009. - Vol. 182. - P. 1463-1468.
Parsons J.K., Kashefi C. Physical activity, benign prostatic hyperplasia, and lower urinary tract symptoms // Eur. Urol. - 2008. - Vol. 53. - P. 1228-1235.
Parsons J.K., Sarma A.V., McVary K., Wei J.T. Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions // J. Urol. - 2013. - Vol. 189 (1 Suppl.). - P. 102-106.
Parsons J.K., Schenk J.M., Arnold K.B. et al. Finasteride reduces the risk of incident clinical benign prostatic hyperplasia // Eur. Urol. - 2012. - Vol. 62. - P. 234-241.
Platz E.A., Rimm E.B., Kawachi I. et al. Alcohol consumption, cigarette smoking, and risk of benign prostatic hyperplasia // Am J Epidemiol. - 1999. - Vol. 149. - P. 106-115.
Prabhat P., Tewari R., Natu S.M. et al. Is central obesity, hyperinsulinemia and dyslipidemia associated with high-grade prostate cancer? A descriptive cross-sectional study // Indian J. Urol. - 2010. - Vol. 26. - P. 502-506.
Rohrmann S., Smit E., Giovannucci E., Platz E.A. Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III) // Int. J Obes. - 2005. - Vol. 29. - P. 310-316.
Rota M., Scotti L., Turati F. et al. Alcohol consumption and prostate cancer risk: a meta-analysis of the dose-risk relation // Eur. J. Cancer Prev. - 2012. - Vol. 21. - P. 350-359.
Saito K., Kihara K. C-reactive protein as a biomarker for urological cancers // Nat. Rev. Urol. - 2011. - Vol. 8. -P. 659-666.
Schenk J.M., Kristal A.R., Arnold K.B. et al. Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial // Am. J Epidemiol. - 2011. - Vol. 173. - P. 1419-1428.
Schenk J.M., Kristal A.R., Neuhouser M.L. et al. Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial // Am. J. Epidemiol. - 2010. - Vol. 171. - P. 571-582.
Schwarz S., Obermller-Jevic U.C., Hellmis E. et al. Lycopene inhibits disease progression in patients with benign prostate hyperplasia // J. Nutr. - 2008. - Vol. 138. - P. 49-53.
Shenouda N.S., Sakla M.S., Newton L.G. et al. Phytosterol Pygeum africanum regulates prostate cancer in vitro and in vivo // Endocrine. - 2007. - Vol. 31. - P. 72-81.
Shukla S., MacLennan G.T., Flask C.A. et al. Blockade of beta-catenin signaling by plant flavonoid apigenin suppresses prostate carcinogenesis in TRAMP mice // Cancer Res. - 2007. - Vol. 67. - P. 6925-6935.
Stacewicz-Sapuntzakis M., Borthakur G., Burns J.L., Bowen P.E. Correlations of dietary patterns with prostate health // Mol. Nutr. Food Res. - 2008. - Vol. 52. - P. 114-130.
St. Sauver J.L., Jacobson D.J., McGree M.E. et al. Protective association between nonsteroidal antiinflammatory drug use and measures of benign prostatic hyperplasia // Am. J. Epidemiol. - 2006. - Vol. 164. - P. 760-768.
Thompson I.M., Klein E.A., Lippman S.M. et al. Prevention of prostate cancer with finasteride: US/European perspective // Eur Urol. - 2003. - Vol. 44. - P. 650-655.
Torre L.A., Siegel R.L., Ward E.M., Jemal A. Global cancer incidence and mortality rates and trends - an update // Cancer Epidemiol. Biomarkers Prev. - 2016. - Vol. 25. - P. 16-27.
Travis R.C., Spencer E.A., Allen N.E. et al. Plasma phyto-oestrogens and prostate cancer in the European Prospective Investigation into Cancer and Nutrition // Br. J. Cancer. - 2009. - Vol. 100. - P. 1817-1823.
Tsuchiya N., Wang L., Horikawa Y. et al. CA repeat polymorphism in the insulin-like growth factor-I gene is associated with increased risk of prostate cancer and benign prostatic hyperplasia // Int. J. Oncol. - 2005. - Vol. 26. - P. 225-231.
van der Sluis T.M., Vis A.N., van Moorselaar R.J. et al. Intraprostatic testosterone and dihydrotestosterone. Part I: concentrations and methods of determination in men with benign prostatic hyperplasia and prostate cancer // BJU Int. - 2012. - Vol. 109. - P. 176-182.
van Hemelrijck M., Garmo H., Holmberg L. et al. Prostate cancer risk in the Swedish AMORIS study: the interplay among triglycerides, total cholesterol, and glucose // Cancer. - 2011. - Vol. 117. - P. 2086-2095.
Wadsworth T.L., Worstell T.R., Greenberg N.M., Roselli C.E. Effects of dietary saw palmetto on the prostate of transgenic adenocarcinoma of the mouse prostate model (TRAMP) // Prostate. - 2007. - Vol. 67. - P. 661-673.
Wei M.Y., Giovannucci E.L. Lycopene, tomato products, and prostate cancer incidence: a review and reassessment in the PSA screening era // J. Oncol. - 2012. -Vol. 2012: 271063.
Wong S.Y., Lau W.W., Leung P.C. et al. The association between isoflavone and lower urinary tract symptoms in elderly men // Br. J. Nutr. - 2007. - Vol. 98. - P. 1237-1242.
Yun S.J., Min B.D., Kang H.W. et al. Elevated insulin and insulin resistance are associated with the advanced pathological stage of prostate cancer in Korean population // J. Korean Med. Sci. - 2012. - Vol. 27. - P. 1079-1084.
All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...